AMRX · Insider Trading
Amneal Pharmaceuticals, Inc. Class A Common Stock
Every open-market purchase and sale reported by AMRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-21 | J Kevin Buchi | Director | G | −20,445 | — |
| 2026-09-14 | J Kevin Buchi | Director | M | +20,445 | +$295.43K |
| 2026-09-02 | Andrew S Boyer | Executive Vice President | G | −80,000 | — |
| 2026-08-25 | Andrew S Boyer | Executive Vice President | G | −152,426 | — |
| 2026-08-14 | John Kiely | Director | MIXED | −60,000 | −$882.00K |
| 2026-08-13 | Nikita Shah | Executive Vice President | Sell | −146,403 | −$2.56M |
| 2026-08-13 | J Kevin Buchi | Director | M | −168,573 | −$2.90M |
| 2026-08-13 | Jason B. Daly | EVP, Chief Legal Officer | Sell | −216,613 | −$3.77M |
| 2026-08-12 | Gautam Patel | Director | A | +283,632 | — |
| 2026-08-12 | Chintu Patel | Co-CEO | A | +6,381,734 | — |
| 2026-08-12 | Tushar Bhikhubhai Patel | 10%+ Owner | A | +12,763,469 | — |
| 2026-08-12 | Chirag K. Patel | President & Co-CEO | A | +6,381,734 | — |
| 2026-05-12 | Deborah M. Autor | Director | Sell | −34,819 | −$450.56K |
| 2026-05-08 | Paul M Meister | Director | M | +48,747 | — |
| 2026-05-08 | J Kevin Buchi | Director | M | +34,819 | — |
| 2026-05-08 | Gautam Patel | Director | M | +34,819 | — |
| 2026-05-08 | Ted C Nark | Director | M | +34,819 | — |
| 2026-05-08 | John Kiely | Director | M | +34,819 | — |
| 2026-05-08 | Deborah M. Autor | Director | M | +34,819 | — |
| 2026-05-08 | Shlomo Yanai | Director | M | +34,819 | — |
| 2026-05-08 | Jeffrey P. George | Director | M | +34,819 | — |
| 2026-03-27 | Chintu Patel | Co-CEO | A | +544,663 deriv. | — |
| 2026-03-27 | Chirag K. Patel | President & Co-CEO | A | +544,663 deriv. | — |
| 2026-03-05 | Jason B. Daly | EVP, Chief Legal Officer | MIXED | +241,178 | −$2.47M |
| 2026-03-05 | Andrew S Boyer | Executive Vice President | MIXED | +273,646 | −$3.66M |
| 2026-03-05 | Chintu Patel | Co-CEO | MIXED | +524,488 | −$4.82M |
| 2026-03-05 | Nikita Shah | Executive Vice President | MIXED | +253,390 | −$3.40M |
| 2026-03-05 | Tasos Konidaris | Executive Vice President & CFO | MIXED | +327,282 | −$4.08M |
| 2026-03-05 | Chirag K. Patel | President & Co-CEO | MIXED | +535,490 | −$4.67M |
| 2026-03-03 | Chintu Patel | Co-CEO | A | +544,663 deriv. | — |
| 2026-03-03 | Jason B. Daly | EVP, Chief Legal Officer | A | +130,718 deriv. | — |
| 2026-03-03 | Chirag K. Patel | President & Co-CEO | A | +544,663 deriv. | — |
| 2026-03-03 | Andrew S Boyer | Executive Vice President | A | +130,718 deriv. | — |
| 2026-03-03 | Tasos Konidaris | Executive Vice President & CFO | A | +145,244 deriv. | — |
| 2026-03-03 | Nikita Shah | Executive Vice President | A | +130,718 deriv. | — |
| 2025-11-19 | Ted C Nark | Director | Sell | −50,000 | −$586.00K |
| 2025-11-14 | Nikita Shah | Executive Vice President | MIXED | — | −$1.21M |
| 2025-08-28 | John Kiely | Director | Sell | −32,000 | −$295.36K |
| 2025-08-25 | Nikita Shah | Executive Vice President | Sell | −120,832 | −$1.17M |
| 2025-08-22 | Andrew S Boyer | Executive Vice President | MIXED | −104,244 | −$2.14M |
| 2025-08-15 | Tasos Konidaris | Executive Vice President & CFO | Sell | −499,730 | −$4.66M |
| 2025-08-15 | Nikita Shah | Executive Vice President | Sell | −71,694 | −$666.04K |
| 2025-08-13 | Andrew S Boyer | Executive Vice President | Sell | −33,436 | −$302.60K |
| 2025-08-13 | Nikita Shah | Executive Vice President | Sell | −50,000 | −$452.00K |
| 2025-08-13 | Jason B. Daly | EVP, Chief Legal Officer | Sell | −22,000 | −$199.10K |
| 2025-06-18 | Gautam Patel | Director | Sell | −94,906 | −$761.15K |
| 2025-06-12 | Gautam Patel | Director | Sell | −56,426 | −$452.54K |
| 2025-05-19 | Nikita Shah | Executive Vice President | Sell | −49,140 | −$372.48K |
| 2025-05-13 | John Kiely | Director | Sell | −50,000 | −$379.50K |
| 2025-05-08 | Jeffrey P. George | Director | M | +40,258 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Tushar Bhikhubhai Patel | 10%+ Owner | 61,341,678 | $1.29B |
| Chirag K. Patel | President & Co-CEO | 22,662,890 | $476.37M |
| Chintu Patel | Co-CEO | 7,770,255 | $163.33M |
| Gautam Patel | Director | 1,927,595 | $40.52M |
| Paul M Meister | Director | 832,800 | $17.51M |
| Jeffrey P. George | Director | 344,614 | $7.24M |
| Ted C Nark | Director | 325,848 | $6.85M |
| Shlomo Yanai | Director | 320,804 | $6.74M |
| Nikita Shah | Executive Vice President | 253,390 | $5.33M |
| Emily Peterson Alva | Director | 211,029 | $4.44M |
| John Kiely | Director | 200,252 | $4.21M |
| Tasos Konidaris | Executive Vice President & CFO | 198,588 | $4.17M |
| Andrew S Boyer | Executive Vice President | 193,646 | $4.07M |
| J Kevin Buchi | Director | 189,021 | $3.97M |
| Deborah M. Autor | Director | 93,660 | $1.97M |
| Jason B. Daly | EVP, Chief Legal Officer | 35,171 | $739.29K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AMRX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.